FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3197115244> ?p ?o ?g. }

• W3197115244 endingPage "S185" @default.
• W3197115244 startingPage "S183" @default.
• W3197115244 abstract "Diffuse large B-cell lymphoma (DLBCL), the most common lymphoid cancer, is curable but has been treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP)-based chemotherapy for decades.1 DLBCL is a heterogeneous disease with distinct subtypes with differential responses to targeted therapy; however, this has not yet translated into standard therapy.2,3 Most frontline DLBCL trials employ an R-CHOP versus R-CHOP + X chemotherapy, which assumes X will either add to or synergize with chemotherapy and not antagonize or have significant added toxicity with chemotherapy.4 Notable examples include lenalidomide, ibrutinib, venetoclax, and bortezomib, among others. Other than rituximab, these trials have been disappointing, despite huge numbers of patients and high response rates in patients with relapsed disease. Moving the field beyond R-CHOP may require a targeted, subgroup-specific approach rather than a one-size-fits-all approach. The analysis of circulating tumor DNA (ctDNA) is a promising technological advance that may enable more flexible/adaptive approaches and should be incorporated into prospective trials.5 Diffuse large B-cell lymphoma (DLBCL), the most common lymphoid cancer, is curable but has been treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP)-based chemotherapy for decades.1 DLBCL is a heterogeneous disease with distinct subtypes with differential responses to targeted therapy; however, this has not yet translated into standard therapy.2,3 Most frontline DLBCL trials employ an R-CHOP versus R-CHOP + X chemotherapy, which assumes X will either add to or synergize with chemotherapy and not antagonize or have significant added toxicity with chemotherapy.4 Notable examples include lenalidomide, ibrutinib, venetoclax, and bortezomib, among others. Other than rituximab, these trials have been disappointing, despite huge numbers of patients and high response rates in patients with relapsed disease. Moving the field beyond R-CHOP may require a targeted, subgroup-specific approach rather than a one-size-fits-all approach. The analysis of circulating tumor DNA (ctDNA) is a promising technological advance that may enable more flexible/adaptive approaches and should be incorporated into prospective trials.5" @default.
• W3197115244 created "2021-09-13" @default.
• W3197115244 creator A5021496101 @default.
• W3197115244 creator A5049293438 @default.
• W3197115244 date "2021-09-01" @default.
• W3197115244 modified "2023-09-27" @default.
• W3197115244 title "Innovative Approaches in Untreated DLBCL" @default.
• W3197115244 cites W1970400561 @default.
• W3197115244 cites W2147246240 @default.
• W3197115244 cites W2888203943 @default.
• W3197115244 cites W2946486395 @default.
• W3197115244 cites W2986728179 @default.
• W3197115244 cites W3034162969 @default.
• W3197115244 cites W3094642003 @default.
• W3197115244 cites W3096470811 @default.
• W3197115244 cites W3096607082 @default.
• W3197115244 cites W3101826014 @default.
• W3197115244 cites W3134205746 @default.
• W3197115244 cites W3193420635 @default.
• W3197115244 doi "https://doi.org/10.1016/s2152-2650(21)01259-3" @default.
• W3197115244 hasPublicationYear "2021" @default.
• W3197115244 type Work @default.
• W3197115244 sameAs 3197115244 @default.
• W3197115244 citedByCount "0" @default.
• W3197115244 crossrefType "journal-article" @default.
• W3197115244 hasAuthorship W3197115244A5021496101 @default.
• W3197115244 hasAuthorship W3197115244A5049293438 @default.
• W3197115244 hasConcept C126322002 @default.
• W3197115244 hasConcept C143998085 @default.
• W3197115244 hasConcept C2776694085 @default.
• W3197115244 hasConcept C2776755627 @default.
• W3197115244 hasConcept C2777938653 @default.
• W3197115244 hasConcept C2778461978 @default.
• W3197115244 hasConcept C2778559949 @default.
• W3197115244 hasConcept C2778720950 @default.
• W3197115244 hasConcept C2779338263 @default.
• W3197115244 hasConcept C2779429289 @default.
• W3197115244 hasConcept C2779725641 @default.
• W3197115244 hasConcept C2779878957 @default.
• W3197115244 hasConcept C2780653079 @default.
• W3197115244 hasConcept C2781303535 @default.
• W3197115244 hasConcept C71924100 @default.
• W3197115244 hasConceptScore W3197115244C126322002 @default.
• W3197115244 hasConceptScore W3197115244C143998085 @default.
• W3197115244 hasConceptScore W3197115244C2776694085 @default.
• W3197115244 hasConceptScore W3197115244C2776755627 @default.
• W3197115244 hasConceptScore W3197115244C2777938653 @default.
• W3197115244 hasConceptScore W3197115244C2778461978 @default.
• W3197115244 hasConceptScore W3197115244C2778559949 @default.
• W3197115244 hasConceptScore W3197115244C2778720950 @default.
• W3197115244 hasConceptScore W3197115244C2779338263 @default.
• W3197115244 hasConceptScore W3197115244C2779429289 @default.
• W3197115244 hasConceptScore W3197115244C2779725641 @default.
• W3197115244 hasConceptScore W3197115244C2779878957 @default.
• W3197115244 hasConceptScore W3197115244C2780653079 @default.
• W3197115244 hasConceptScore W3197115244C2781303535 @default.
• W3197115244 hasConceptScore W3197115244C71924100 @default.
• W3197115244 hasLocation W31971152441 @default.
• W3197115244 hasOpenAccess W3197115244 @default.
• W3197115244 hasPrimaryLocation W31971152441 @default.
• W3197115244 hasRelatedWork W160156331 @default.
• W3197115244 hasRelatedWork W1970150235 @default.
• W3197115244 hasRelatedWork W2110489999 @default.
• W3197115244 hasRelatedWork W2551481738 @default.
• W3197115244 hasRelatedWork W2888800187 @default.
• W3197115244 hasRelatedWork W3026939985 @default.
• W3197115244 hasRelatedWork W4236815493 @default.
• W3197115244 hasRelatedWork W4244051174 @default.
• W3197115244 hasRelatedWork W4284698212 @default.
• W3197115244 hasRelatedWork W2183308400 @default.
• W3197115244 hasVolume "21" @default.
• W3197115244 isParatext "false" @default.
• W3197115244 isRetracted "false" @default.
• W3197115244 magId "3197115244" @default.
• W3197115244 workType "article" @default.